Himbacine-derived thrombin receptor antagonists: C7-Spirocyclic analogues of vorapaxar

ACS Medicinal Chemistry Letters

Volumn 5, Issue 5, 2014, Pages 561-565

  Chelliah, Mariappan V ^a   Eagen, Keith ^a   Guo, Zhuyan ^a   Chackalamannil, Samuel ^a,b   Xia, Yan ^a,c   Tsai, Hsingan ^a   Greenlee, William J ^a,d   Ahn, Ho Sam ^a   Kurowski, Stan ^a   Boykow, George ^a   Hsieh, Yunsheng ^a   Chintala, Madhu ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c QINGDAO TECHNOLOGICAL UNIVERSITY   (China)

^d MedChem Discovery Consulting LLC   (United States)

Author keywords

himbacine; PAR 1 antagonist; thrombin receptor; vorapaxar

Indexed keywords

C 7 SPIROCYCLIC DERIVATIVE; HIMBACINE; PROTEINASE ACTIVATED RECEPTOR 1; UNCLASSIFIED DRUG; VORAPAXAR;

ANIMAL EXPERIMENT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION; X RAY;

EID: 84900445133     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500008w     Document Type: Article

References (23)

1. David, G.; Patrono, C. Platelet Activation and Atherothrombosis N. Engl. J. Med. 2007, 357, 2482-2494
2. Miner, J.; Hoffhines, A. The Discovery of Aspirin's Antithrombotic Effects Tex. Heart Inst. J. 2007, 34 (2) 179-186
3. Testa, L.; Biondi Zoccai, G. G.; Valgimigli, M.; Latini, R. A.; Pizzocri, S.; Lanotte, S.; Laudisa, M. L.; Brambilla, N.; Ward, M. R.; Figtree, G. A.; Bedogni, F.; Bhindi, R. Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents Adv. Hematol. 2010, 595934
4. Chackalamannil, S.; Xia, Y.; Greenlee, W. J.; Clasby, M.; Doller, D.; Tsai, H.; Asberom, T.; Czarniecki, M.; Ahn, H.-S.; Boykow, G.; Foster, C.; Agans-Fantuzzi, J.; Bryant, M.; Lau, J.; Chintala, M. Discovery of Potent Orally Active Thrombin Receptor (Protease Activated Receptor 1) Antagonists as Novel Antithrombotic Agents J. Med. Chem. 2005, 48, 5884-5887
5. Clasby, M. C.; Chackalamannil, S.; Czarniecki, M.; Doller, D.; Eagen, K.; Greenlee, W.; Kao, G.; Lin, Y.; Tsai, H.; Xia, Y.; Ahn, H.-S.; Agans-Fantuzzi, J.; Boykow, G.; Chintala, M.; Foster, C.; Smith-Torhan, A.; Alton, K.; Bryant, M.; Hsieh, Y.; Lau, J.; Palamanda, J. Metabolism-Based Identification of a Potent Thrombin Receptor Antagonist J. Med. Chem. 2007, 50, 129-138
6. Chelliah, M. V.; Chackalamannil, S.; Xia, Y.; Eagen, K.; Clasby, M. C.; Gao, X.; Greenlee, W. J.; Ahn, H.-S.; Agans-Fantuzzi, J.; Boykow, G.; Hsieh, Y.; Bryant, M.; Palamanda, J.; Chan, T.-M.; Hesk, D.; Chintala, M. Heterotricyclic Himbacine Analogues as Potent, Orally Active Thrombin Receptor (Protease Activated Receptor-1) Antagonists J. Med. Chem. 2007, 50 (21) 5147-5160
7. Clasby, M. C.; Chackalamannil, S.; Czarniecki, M.; Doller, D.; Eagen, K.; Greenlee, W. J.; Lin, Y.; Tagat, J. R.; Tsai, H.; Xia, Y.; Ahn, H.; Agans-Fantuzzi, J.; Boykow, G.; Chintala, M.; Hsieh, Y.; McPhail, A. T. Himbacine Derived Thrombin Receptor Antagonists: Discovery of a New Tricyclic Core Bioorg. Med. Chem. Lett. 2007, 17 (13) 3647-3651
8. Chackalamannil, S.; Wang, Y.; Greenlee, W. J.; Hu, Z.; Xia, Y.; Ahn, H.; Boykow, G.; Hsieh, Y.; Palamanda, J.; Agans-Fantuzzi, J.; Kurowski, S.; Graziano, M.; Chintala, M. Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity J. Med. Chem. 2008, 51 (11) 3061-3064
9. Xia, Y.; Chackalamannil, S.; Greenlee, W. J.; Wang, Y.; Hu, Z.; Root, Y.; Wong, J.; Kong, J.; Ahn, H.; Boykow, G.; Hsieh, Y.; Kurowski, S.; Chintala, M. Discovery of a Vorapaxar Analog with Increased Aqueous Solubility Bioorg. Med. Chem. Lett. 2010, 20 (22) 6676-6679
10. Chelliah, M. V.; Chackalamannil, S. L.; Xia, Y.; Eagen, K.; Greenlee, W. J.; Ahn, H.; Agans-Fantuzzi, J.; Boykow, G.; Hsieh, Y.; Bryant, M.; Chan, T.; Chintala, M. Discovery of Nor-Seco Himbacine Analogues as Thrombin Receptor Antagonists Bioorg. Med. Chem. Lett. 2012, 22 (7) 2544-2549
11. Chackalamannil, S. L. Antiplatelet Agents. In Burger's Medicinal Chemistry, Drug Discovery, and Development, 7 th ed.; Abraham, D. J.; Rotella, D. P., Eds.; Wiley: New York, 2010; pp 409-476.
12. Coughlin, S. R. Protease-Activated Receptors in Handbook of Cell Signaling; Bradshaw, R. A.; Dennis, E. A., Eds.; Elsevier: San Diego, CA, 2004; Vol. 1, pp 167-171.
13. Coughlin, S. R. Cold Spring Harbor Symposia on Quantitative Biology Protease-Activated Receptors in the Cardiovascular System 2002, 67, 197-208
14. Coughlin, S. R. Protease-Activated Receptors in Vascular Biology Thromb. Haemostasis 2001, 86, 298-307
15. Coughlin, S. R. Protease-Activated Receptors in Hemostasis, Thrombosis and Vascular Biology J. Thromb. Haemost. 2005, 3, 1800-1814
16. Chackalamannil, S. Thrombin Receptor (Protease Activated Receptor-1) Antagonists as Potent Antithrombotic Agents with Strong Antiplatelet Effects J. Med. Chem. 2006, 49, 5389-5403
17. Grand, R. J.; Turnell, A. S; Grabham, P. W. Cellular Consequences of Thrombin-Receptor Activation Biochem. J. 1996, 313, 353-368
18. Tricoci, P.; Huang, Z.; Held, C.; Moliterno, D. J.; Armstrong, P. W.; Van de Werf, F.; White, H. D.; Aylward, P. E.; Wallentin, L.; Chen, E.; Lokhnygina, Y.; Pei, J.; Leonardi, S.; Rorick, T. L.; Kilian, A. M.; Jennings, L. H. K.; Ambrosio, G.; Bode, C.; Cequier, A.; Cornel, J. H.; Diaz, R.; Erkan, A.; Huber, K.; Hudson, M. P.; Jiang, L.; Jukema, J. W.; Lewis, B. S.; Lincoff, A. M.; Montalescot, G.; Nicolau, J. C.; Ogawa, H.; Pfisterer, M.; Prieto, J. C.; Ruzyllo, W.; Sinnaeve, P. R.; Storey, R. F.; Valgimigli, M.; Whellan, D. J.; Widimsky, P.; Strony, J.; Harrington, R. A.; Mahaffey, K. W.; TRACER Investigators. Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes N. Engl. J. Med. 2012, 366 (15) 20-33
19. Morrow, D. A.; Braunwald, E.; Bonaca, M. P.; Ameriso, S. F.; Dalby, A. J.; Fish, M. P.; Fox, K. A.; Lipka, L. J.; Liu, X.; Nicolau, J. C.; Ophuis, A. J.; Paolasso, E.; Scirica, B. M.; Spinar, J.; Theroux, P.; Wiviott, S. D.; Strony, J.; Murphy, S. A.; TRA 2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the Secondary Prevention of Atherothrombotic Events N. Engl. J. Med. 2012, 366 (15) 1404-1413
20. Ghosal, A.; Lu, X.; Penner, N.; Gao, L.; Ramanathan, R.; Chowdhury, S. K.; Kishnani, N. S.; Alton, K. B. Identification of Human Liver Cytochrome P450 Enzymes Involved in the Metabolism of SCH 530348 (Vorapaxar), a Potent Oral Thrombin Protease-Activated Receptor 1 Antagonist Drug Metab. Dispos. 2011, 39, 30-38
21. Espino, C. G.; Du Bois, J. A Rh-Catalyzed C-H Insertion Reaction for the Oxidative Conversion of Carbamates to Oxazolidinones Angew. Chem., Int. Ed. 2001, 40, 598-600
22. Ahn, H.-S.; Foster, C.; Boykow, G.; Arik, L.; Smith-Torhan, A.; Hesk, D.; Chatterjee, M. Binding of a Thrombin Receptor Tethered Ligand Analogue to Human Platelet Thrombin Receptor Mol. Pharmacol. 1997, 51, 350-356
23. Zhang, C.; Srinivasan, Y.; Arlow, D. H.; Fung, J. J.; Palmer, D.; Zheng, Y.; Green, H. F.; Pandey, A.; Dror, R. O.; Shaw, D. E.; Weis, W. I.; Coughlin, S. R.; Kobilka, B. K. High-Resolution C Structure of Human Protease-Activated Receptor Nature 2012, 492, 387-392